Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy-Reference-Cited by-同舟云学术

Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy

Published:2018-08 Issue:8 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Quinn Melissa¹,Fannin J. T.¹,Sciasci Joseph¹,Bragg Allison¹,Campbell Patrick K.²,Carias Delia¹,Crews Kristine R.¹,Gregornik David¹,Jeha Sima²,Maron Gabriela³,Pauley Jennifer L.¹,Swanson Hope D.¹,Wolf Joshua³,Greene William¹

Affiliation:

1. Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

2. Department of Oncology, Leukemia/Lymphoma Division, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

3. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Abstract

Pneumocystis jirovecii pneumonia is a life-threatening opportunistic infection in children receiving immunosuppressive chemotherapy. Without prophylaxis, up to 25% of pediatric oncology patients receiving chemotherapy will develop Pneumocystis jirovecii pneumonia.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00173-18

Reference22 articles.

1. Successful Chemoprophylaxis forPneumocystis cariniiPneumonitis

2. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia

3. Pentamidine Isethionate in the Treatment of Pneumocystis carinii Pneumonia